August 26th 2025
Read the full, exclusive transcript from the inaugural "Brain Trust: Conversations in Clinical Psychopharmacology" video with Joseph F. Goldberg, MD, and Marlene Freeman, MD.
TEV-'749: An Option to Serve an Important Treatment Gap for Patients With Schizophrenia
October 14th 2024Learn more about the new positive efficacy, safety, tolerability data from the phase 3 SOLARIS trial, which were presented at the 37th Annual European College of Neuropsychopharmacology Congress.
Read More
Poll: Do You Feel Prepared to Prescribe the Newly Approved First-In-Class Muscarinic Agonist?
September 27th 2024The first-in-class muscarinic agonist Cobenfy, formerly known as KarXT, was just approved by the FDA to treat schizophrenia in adults. Are you ready to discuss it with patients and caregivers?
Read More
Twenty Years of Using and Contributing to the Model Curriculum for Psychopharmacology Teachers
September 4th 2024Although the Model Curriculum for Teachers of Psychopharmacology has evolved over 2 decades, it continues to provide practical and easy to use resources for psychiatric educators from leading experts.
Read More
The Safety of Psychostimulants or Atomoxetine for Patients With Psychotic Disorders
Evidence indicates that children and adolescents with ADHD have a more than 4-fold increased risk of schizophrenia spectrum and other psychotic disorders in adulthood compared with the general population.
Read More
Treatment Options for the Management of Behavioral and Psychological Symptoms of Dementia
The behavioral and psychological symptoms of dementia contribute significantly to the greater rates morbidity and mortality among those with dementia.
Read More